Wesana Health Holdings Inc is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The Company is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.